Victoria Cuebas Hiner, DO | |
1000 Harrington St, Mount Clemens, MI 48043-2920 | |
(586) 790-9003 | |
Not Available |
Full Name | Victoria Cuebas Hiner |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 1000 Harrington St, Mount Clemens, Michigan |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1588287742 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 5151014607 (Michigan) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Victoria Cuebas Hiner, DO 1000 Harrington St, Mount Clemens, MI 48043-2920 Ph: (586) 790-9003 | Victoria Cuebas Hiner, DO 1000 Harrington St, Mount Clemens, MI 48043-2920 Ph: (586) 790-9003 |
News Archive
Mutations in RAS proteins initiate many of the most aggressive tumors, and the search for pharmacological inhibitors of these proteins has become a priority in the battle against cancer. Michail Steklov, Francesca Baietti, and colleagues from the Anna Sablina lab identified LZTR1 as an evolutionarily conserved component of the RAS pathway.
To honor the memory of a longtime leader in glaucoma treatment and research, the ARVO Foundation for Eye Research will present the Dr. David L. Epstein Award. The new award — a $100,000 prize — was established by the late Dr. Epstein's family and will be presented annually to a senior-level glaucoma researcher at the ARVO Annual Meeting.
Although endocrine therapy for breast cancer has shown excellent results in controlling the disease, responsiveness to the therapy depends on whether or not there is expression of estrogen receptors in breast cancer cells. Research from the Sbarro Institute for Cancer Research and Molecular Medicine, a nonprofit cancer, cardiovascular and diabetes research center located in Philadelphia, PA, reports on the effectiveness of a new molecule, Scriptaid, that restores receptivity to endocrine therapy in breast cancer cell lines that had tested negative for the expression of estrogen receptors.
This is the million dollar question but it is hard to give a definite answer. Most data on trends in life and healthy life expectancy use surveys that do not include people in care homes which can skew results at older ages.
› Verified 5 days ago